Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

14.01.2019 | consensus report | Ausgabe 1-2/2019 Open Access

Wiener klinische Wochenschrift 1-2/2019

Immunosuppressives and biologics during pregnancy and lactation

A consensus report issued by the Austrian Societies of Gastroenterology and Hepatology and Rheumatology and Rehabilitation

Wiener klinische Wochenschrift > Ausgabe 1-2/2019
Antonia Puchner, Hans Peter Gröchenig, Judith Sautner, Yvonne Helmy-Bader, Herbert Juch, Sieglinde Reinisch, Christoph Högenauer, Robert Koch, Josef Hermann, Andrea Studnicka-Benke, Wolfgang Weger, Rudolf Puchner, MD Prof. Clemens Dejaco


An increasing and early-onset use of immunosuppressives and biologics has become more frequently seen among patients with inflammatory bowel diseases (IBD) and rheumatic disorders. Many women in their childbearing years currently receive such medications, and some of them in an interdisciplinary setting. Many questions arise in women already pregnant or wishing to conceive with respect to continuing or discontinuing treatment, the risks borne by the newborns and their mothers and long-term safety. Together with the Austrian Society of Rheumatology and Rehabilitation, the IBD working group of the Austrian Society of Gastroenterology and Hepatology has elaborated consensus statements on the use of immunosuppressives and biologics in pregnancy and lactation. This is the first Austrian interdisciplinary consensus on this topic. It is intended to serve as a basis and support for providing advice to our patients and their treating physicians.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 1-2/2019

Wiener klinische Wochenschrift 1-2/2019 Zur Ausgabe

mitteilungen der gesellschaft der ärzte in wien